Author + information
- Received December 1, 2017
- Revision received June 4, 2018
- Accepted July 12, 2018
- Published online May 6, 2019.
- Frank E. Corrigan III, MDa,
- Patrick T. Gleason, MDb,
- Jose F. Condado, MDb,
- John C. Lisko, MDb,
- John H. Chen, MDb,
- Norihiko Kamioka, MDb,
- Patricia Keegan, DNPb,
- Sharon Howell, RDCSb,
- Stephen D. Clements Jr., MDb,
- Vasilis C. Babaliaros, MDb and
- Stamatios Lerakis, MDc,∗ ()
- aCardiovascular Medicine, Wellstar Medical Group, Marietta, Georgia
- bDivision of Cardiology, Emory University School of Medicine, Atlanta, Georgia
- cIcahn School of Medicine at Mount Sinai, New York, New York
- ↵∗Address for correspondence:
Dr. Stamatios Lerakis, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York 10029.
• Multimodality imaging is critical for the safe performance of TAVR.
• The appropriate use of multimodal imaging can predict, detect and, when needed, assist in the management of complications from TAVR.
• Fusing imaging techniques together with the advancements in valve technology will continue to safeguard the field of TAVR.
The management of patients with valvular heart disease is increasingly reliant on multimodal cardiac imaging. In patients with severe aortic stenosis considered for transcatheter aortic valve replacement, careful pre-procedural planning with multimodal imaging is necessary to avoid and prevent complications during the procedure. During or immediately after the procedure, rapid echocardiographic assessment is important to assess the new valve’s function and manage major complications. Echocardiography, cardiac computed tomography, and cardiac magnetic resonance imaging all share important roles in the post-procedural evaluation of abnormal transcatheter valve function. This review discusses the use of multimodal imaging for predicting, detecting, and managing complications after TAVR.
- interventional echocardiography
- paravalvular leak
- structural heart interventions
- transcatheter aortic valve replacement
Drs. Babaliaros and Lerakis are consultants for Abbott Vascular and Edwards Lifesciences. Ms. Howell is a consultant for Abbott Vascular. Dr. Keegan is a speaker for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received December 1, 2017.
- Revision received June 4, 2018.
- Accepted July 12, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.